3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Status
Recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Other hematologic neoplasm
1
Conditions
Leukemia, Promyelocytic, Acute
3
Thrombocytopenia
2
Pathologic Complete Response
2
Uterine Cervical Neoplasms
1
Pancreatic Neoplasms
1
Ovarian Neoplasms
1
Oropharyngeal Neoplasms
1
Neoplasms
1
Multiple Myeloma
1
Lung Neoplasms
1
Leukemia
1
Laryngeal Neoplasms
1
Hypopharyngeal Neoplasms
1
Hematologic Neoplasms
1
Hematologic Diseases
1
Head and Neck Neoplasms
1
Gastrointestinal Neoplasms
1
Fallopian Tube Neoplasms
1
Endometrial Neoplasms
1
Digestive System Neoplasms
1
Colorectal Neoplasms
1
Carcinoma, Non-Small-Cell Lung
1
Breast Neoplasms
1
Interventions
Cyclophosphamide
15
fludarabine
12
Mycophenolic Acid
10
Standard of Care
9
Whole-Body Irradiation
7
Tacrolimus
7
venetoclax
6
Specimen Handling
6
Sirolimus
6
Practice Guidelines as Topic
6
trametinib
5
Melphalan
5
fludarabine phosphate
4
Mesna
4
Magnetic Resonance Spectroscopy
4
Filgrastim
4
Biopsy
4
Behavior Therapy
4
Azacitidine
4
Thiotepa
3
Peripheral Blood Stem Cell Transplantation
3
GSK2636771
3
Educational Status
3
Crizotinib
3
Busulfan
3
thymoglobulin
2
talquetamab
2
ruxolitinib
2
palbociclib
2
osimertinib
2
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Hematologic Neoplasms
×
Tretinoin
×
90 days
×
Clear all
NCT07504458
2026-04-16
QUATRO-APL
Quetzal Therapeutics
Phase 3
Recruiting
150 enrolled